Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Suffer Losses After Molycorp Was Downgraded By JPM

Molycorp, Inc. (MCP) slides more than 13% today after the company had its price target lowered by JPMorgan Chase & Co. from $57.00 to $39.00. Now Molycorp has a “Neutral” rating. MCP is trading at $24.23 at 2:53PM EST on Wednesday, which is a 13.46% or $3.77 decline from its close price of $20.46 on Tuesday.

CHILTON INVESTMENT COMPANY

Here is a list of hedge funds that may suffer big losses due to MCP’s downgrading.

1. JAT Capital Management – John Thaler: loses $19.10 million

2. Chilton Investment Company – Richard Chilton: loses $3.97 million

3. Aletheia Research and Management – Peter J. Eichler Jr.       : loses $2.41 million

4. Coatue Management – Philippe Laffont: loses $1.50 million

5. Ardsley Partners – Philip Hempleman: loses $829 thousand

6. Citadel Investment Group – Ken Griffin: loses $763 thousand

7. Driehaus Capital – Richard Driehaus: loses $631 thousand

8. Angelo Gordon & Co – John M. Angelo and Michael L. Gordon: loses $518 thousand

9. Moore Global Investments – Louis Bacon: loses $207 thousand

10. Adage Capital Management – Phill Gross and Robert Atchinson: loses $189 thousand

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in MCP since the end of September. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!